Spectrum Pharmaceuticals Highlights Four Abstracts at the 58th Annual Meeting of the American Society of Hematology (ASH) in ...
December 02 2016 - 6:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced key presentations of clinical and scientific data related
to its products at the 58th Annual Meeting of the American Society
of Hematology (ASH), being held in San Diego, California, from
December 3-6, 2016.
For more information about the ASH annual meeting and for a
complete list of abstracts, please refer to the conference website
at https://ash.confex.com/ash/2016/webprogram/start.html.
The following are key PTCL-related abstracts being presented at
the ASH meeting:
Abstract # Type
Title First Author
Date/TimeLocation
4149 Poster Case Match Control
Analysis of Propel Reveals Survival Advantage for Patients with
Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated
with Pralatrexate O’Connor
Monday, Dec 5,6:00 PM-8:00 PMHall GH
4150 Poster Differential Outcome
of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell
Lymphoma: Analysis from a Prospective Multicenter US Cohort Study
Lansigan
Monday, Dec 5,6:00 PM-8:00 PMHall GH
1824 Poster The Pralatrexate -
Romidepsin Doublet: A Well Tolerated and Highly Effective
Combination for Patients with Relapsed or Refractory Peripheral
T-Cell Lymphoma Amengual
Saturday, Dec 3,5:30 PM-7:30 PMHall GH
The following key ZEVALIN® (ibritumomab tiuxetan)-related
abstract will be presented at the ASH conference:
Abstract # Type
Title First Author
Location 1793 Poster
Short Course of Bendamustine and Rituximab Followed By
90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive
Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and
Progression Free Survival Costa
Saturday, Dec 3,5:30 PM-7:30 PMHall GH
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in Hematology and Oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the Company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and
Exchange Commission. The Company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC® and ZEVALIN® are registered
trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are
trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161202005132/en/
Spectrum Pharmaceuticals, Inc.Shiv Kapoor, 702-835-6300Vice
President, Strategic Planning & Investor
RelationsInvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2024 to May 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From May 2023 to May 2024